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Abstract Background: Circulatory neutrophils have been
reported to be activated in preeclampsia. It has been
suggested that maternal plasma levels of elastase may
serve as a possible cell-free marker to quantify such
activation. Although plasma elastase levels have been
found to be elevated in cases with manifest preeclampsia
and eclampsia, this has not yet been examined in cases
with early and late onset preeclampsia. We have now
examined this aspect. Methods: In this retrospective
study, maternal plasma samples were examined from
eight cases with early onset preeclampsia (<34 weeks of
gestation), eight cases with late onset preeclampsia
(>34 weeks of gestation) and an equal number of ges-
tational age matched normotensive term controls. Plas-
ma concentrations of elastase were measured by ELISA
using a commercially available assay. Results: Plasma
elastase concentrations were signiﬁcantly elevated the
preeclampsia study group when compared to the nor-
motensive control group (median=139.2 ng/ml versus
median=72.1 ng/ml; P=0.0025). These elevations re-
mained signiﬁcant when the preeclampsia study group
was stratiﬁed into case with early onset preeclampsia
(median=118.8 ng/ml versus median=62.2 ng/ml;
P=0.03), but jailed failed to attain signiﬁcance for those
cases with late onset preeclampsia (median=181.3 ng/
ml versus median=86.3 ng/ml; P=0.061). Conclusions:
Our data indicate that elastase levels are elevated in both
early and late onset forms of preeclampsia, and imply
that the activation of neutrophils may be more acute in
the former than in the latter (238 words).
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Introduction
Despite intensive research, preeclampsia continues to be
a leading cause of feto-maternal mortality and morbidity
in the developed and developing world [1, 2]. Current
consensus is that the disorder is initiated by a placental
defect, which triggers a cascade of events leading to the
maternal syndrome [1, 2]. These events include an overt
activation of the maternal innate immune system, pos-
sibly due the elevated shedding of syncytiotrophoblast-
derived microparticles (frequently termed STBM), as
well as an imbalance in placenta-derived angiogenic
factors [1, 2].
Neutrophils have previously been characterized as
one of the major cell types of the maternal innate im-
mune system to be activated in preeclampsia [3–5].
Characteristically these cells play a major role in the
clearing of bacterial and viral infections, and are pre-
dominant in the immediate cellular inﬁltration of
inﬂammatory sites. Neutrophils are capable of phago-
cytosing foreign elements such as bacteria, destroying
them via the expression of a number of bacteriocidal
substances, which include highly reactive toxic oxygen
species, proteases, phospholipases and defensins. Their
uncontrolled activation and degranulation can, how-
ever, lead to considerable tissue damage, and this feature
has been implicated in the wide-spread damage of the
maternal endothelium which occurs in preeclampsia [5].
Evidence for the activation of neutrophils in pre-
eclampsia has been obtained using ﬂow cytometry to
measure the expression of cell surface activation mark-
ers, such as CD11b [4], or the intracellular expression of
reactive oxygen species [6]. Soluble markers of neutro-
phil activation include elastase and lactoferrin [3, 7], the
A. K. Gupta Æ W. Holzgreve Æ S. Hahn (&)
Laboratory for Prenatal Medicine,
University Women’s Hospital/Department of Research,
Spitalstrasse 21, CH 4031 Basel, Switzerland
E-mail: shahn@uhbs.ch
Tel.: +41-61-2659224
Fax: +41-61-2659399
S. Gebhardt
Department of Obstetrics and Gynecology,
University of Stellenbosch, Stellenbosch, South Africa
R. Hillermann
Department of Genetics, University of Stellenbosch,
Stellenbosch, South Africa
Arch Gynecol Obstet (2006) 273: 239–242
DOI 10.1007/s00404-005-0093-z
levels of which have been shown to be signiﬁcantly ele-
vated in cases with preeclampsia, especially those with
eclampsia. Additional evidence for aberrant neutrophil
activation in preeclampsia includes data obtained using
in vitro models where placentally derived syncytio-
trophoblast microparticles have been shown to induce
the expression of superoxide radicals in peripheral neu-
trophils [8]. In this context we have recently observed
that STBM will induce the expression of CD11b on
isolated circulatory neutrophils, and that such treatment
also triggers the formation of extracellular DNA lattices
(neutrophil extracellular traps termed NETs) by these
cells [9]. We also found evidence for the dramatic in-
crease in the presence of such NETs directly in the in-
tervillous space of preeclamptic placentae when
compared to placentae from normal term deliveries [9].
As it has recently been suggested that preeclampsia
be stratiﬁed into two distinct categories [10], namely
those with early onset of the disorder (deﬁned as
symptoms prior to 34 weeks of gestation) and late
onset (deﬁned as symptoms prior to 34 weeks of ges-
tation), we wished to assess whether neutrophil acti-
vation diﬀers between these two groups. For our pilot
examination we selected a soluble marker, plasma
elastase, which can be readily measured by commercial
ELISA technology [3, 7].
Materials and methods
Study and control cohorts
This study was performed in a retrospective manner
using samples, which had previously been collected for
the analysis of cell-free fetal nucleic acids [11, 12]. Ap-
proval for this study was granted by the respective
Institutional Review Boards (Basel and Stellenbosch),
and export of biological material was approved by the
South African Department of Health. Written informed
consent was obtained in all instances.
In the present analysis 16 cases with manifest pre-
eclampsia were stratiﬁed according to early (n=8) and
late onset (n=8) forms of the disorder [10]. These were
matched with an equal number of normotensive con-
trols. As in our previous examinations, early onset pre-
eclampsia was deﬁned as onset of disease after 20 weeks
but before 34 weeks of pregnancy, while those with late
onset disease were deﬁned as onset of clinical symptoms
after 34 weeks of an otherwise uneventful pregnancy [11,
12]. Preeclampsia was deﬁned by a blood pressure
measurement of at least 140/90 mm Hg in two deter-
minations at least 4 h apart, using Korotkoﬀ V, or by a
single diastolic blood pressure measurement of more
than 110 mm Hg as well as associated proteinuria of at
least 2+ on diagnostic urine strips (again, two mea-
surements at least 4 h apart) or ‡300 mg protein loss in a
24 h urine collection [11, 12]. The blood samples from
the normotensive control pregnancies were taken at
gestational ages matched to those of the two pre-
eclampsia study groups (n=16).
Plasma elastase analysis
The plasma samples were separated by centrifugation
and stored frozen as described previously [11, 12]. All
samples were shipped by air freight on dry ice from Cape
Town to Basel for analysis. Plasma elastase was deter-
mined using a commercial ELISA kit (Bender MedSys-
tems, Vienna, Austria), with a sensitivity of 0.156–10 ng/
ml. Absorbance was recorded on spectro-photometer
(Molecular Devices, Sunnyvale, CA, USA) using
450 nm as the primary wave length and 620 nm as the
reference wavelength. Data was analyzed using SoftMax
Pro 3.1 software (Molecular Devices).
Statistical analysis
Data were analyzed using SPSS for Windows, using the
Mann–Whitney U-test. P values of less than 0.05 were
considered signiﬁcant. Data are presented by box plots
(Fig. 1), indicating the median value (line in the box),
the 75th and 25th percentiles (limits of box), and the
10th and 90th percentiles (upper and lower horizontal
bars), respectively. One outlier in the cases with late
onset preeclampsia with a value of 575.1 was excluded
from the ﬁgure. This value was not excluded from the
statistical analysis.
Results
Our analysis conﬁrms previous reports [3, 7] that the
levels of plasma elastase are elevated in cases with pre-
eclampsia when compared to the control group (med-
ian=139.2 ng/ml; range=53.1–575.15 ng/ml; n=16
versus median=72.1 ng/ml; range=36.6–108.6 ng/ml;
n=16; P=0.0025). This also held true when the pre-
eclampsia study group was stratiﬁed into cases with
early and late onset forms of the disorder (Table 1 and
Fig. 1) [13, 14]. In this instance, however, the elevations
were only signiﬁcant in the group with early onset pre-
eclampsia (P=0.03), and just failed to attain signiﬁcance
in the group with the late onset form of the disorder
(P=0.06).
Discussion
Part of the motivation for stratifying preeclampsia into
early and late onset forms, is that the former are char-
acterized by higher rates of neonatal mortality and are
associated with a greater degree of maternal morbidity
than the latter form [10]. It has also been determined
that the maternal symptoms associated with the early
form are more severe than those with late onset pre-
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eclampsia, a feature also evident in the current study
(Table 1) [15]. Evidence for the latter was also seen in
our recent studies where we examined the levels of cell-
free fetal and maternal nucleic acids in these conditions,
where these levels were generally higher in the cases with
early onset preeclampsia than in those with late onset
[11].
In our analysis we conﬁrm that plasma elastase levels
are elevated in preeclampsia when compared to control
normotensive pregnancies, thereby providing continuing
evidence for the activation of neutrophils in this disor-
der. A new aspect of our study is that we examined cases
with early and late onset forms of preeclampsia. This
analysis indicated that although plasma elastase levels
were elevated in both forms, these elevations only at-
tained signiﬁcance in the cases with early onset pre-
eclampsia. This latter result may possibly be due to the
small size of our study cohorts (eight cases per group), as
the extent of the elevations in each study group in
comparison to the matched control group was of the
order of twofold. Consequently, it will be necessary to
examine this aspect in a larger study.
Although a host of evidence exist implicating the
activation of neutrophils in preeclampsia, ranging from
the up-regulated expression of cell surface or intracel-
lular activation markers on peripheral circulatory neu-
trophils [4, 6], in vitro models [8], as well as the recent
detection of neutrophil NETs directly in preeclamptic
placentae [9], it is currently not clear whether the acti-
vation of this cell type is an early or late event in the
cascade leading to the development of maternal symp-
toms.
In order to study this particular facet in a large scale
prospective study it will be necessary to apply tools,
which permit the ready assessment of neutrophil acti-
vation in a simple and reliable manner. Although it is
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Fig. 1 Box plot illustrating
plasma elastase concentrations
in cases with early onset
preeclampsia (PET<34), late
onset preeclampsia (PET>34)
and, respectively, matched
control groups (CON<34 and
CON>34). Signiﬁcance is
indicated by *
Table 1 Clinical characteristics of the preeclampsia study and gestational age matched control cohorts
Early pregnancy
controls
Early onset
preeclampsia
Late pregnancy
controls
Late onset
preeclampsia
n 8 8 8 8
Blood pressure: systolic 135 (110–150) 170 (150–220) 120 (100–130) 150 (150–190)
Blood pressure: diastolic 80 (70–80) 105 (90–160) 72.5 (60–80) 100 (90–110)
Gestational age at the time
of blood collection
30 weeks (24–32 weeks) 31 weeks (24–32 weeks) 36 weeks (35–38 weeks) 34.5 weeks (34–38 weeks)
Gestational age at the
time of delivery
39 weeks (37–41 weeks) 31.5 weeks (24–33 weeks) 38 weeks (36–41 weeks) 35 weeks (34–38 weeks)
Fetal weight (g) 3180 (2820–4352) 1425 (476–1760) 3119 (2490–3418) 1880 (1200–2565)
Plasma elastase
concentration (ng/ml)
62.2 (47.0–91.3) 118.8 (48.6–108.6) 86.3 (53.1–240.8) 181.3 (63.3–575.1)
241
highly probably that ﬂow cytometry will provide a more
accurate assessment of the degree of neutrophil activa-
tion in the maternal periphery, such an analysis would
not be feasible for a large scale examination, especially
for samples collected distal to the site of analysis. In this
context, our present data, as well as those of a number of
previous studies indicate that the analysis of plasma
elastase may serve as a useful marker to quantify the
extent of neutrophil activation and degranulation in
preeclampsia. It is therefore possible that such mea-
surements may help address this important question and
thereby assist in increasing our understanding of this
enigmatic disorder.
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